Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Universidad británica busca acuerdos de financiación, investigación y licencia para desarrollar nuevas terapias para tipos de cáncer sin un tratamiento específico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20170215003
Publicado:
06/03/2017
Caducidad:
06/03/2018
Resumen:
Una empresa británica ha estado investigando un nuevo biomarcador, una proteína conocida como Ran-GTPase, para tipos de cáncer que actualmente no tienen tratamientos específicos: cáncer de mama triple negativo, cáncer de pulmón de células no pequeñas resistente a los inhibidores de tirosina quinasa y metástasis de cáncer de pulmón y mama. La proteína desempeña una función importante en el desarrollo y evolución del cáncer y se sobreexpresa en varios tipos de cáncer con importancia pronóstica. Su sobreexpresión está relacionada con una mayor agresividad de las células cancerosas y con la muerte de los pacientes. La universidad busca socios con el fin de establecer acuerdos de financiación, investigación y licencia para continuar con el desarrollo.

Details

Tittle:
Uk based university is seeking financial agreements, research co-operations and licencing agreements for the development of novel therapeutics for cancer types that have no targeted therapies
Summary:
A UK university has been investigating a novel biomarker in cancer, a protein called Ran-GTPase for cancer types that currently have no targeted therapies are looking for financial co-operations, research co-operations and licencing agreements for further development.

Description:
The university is addressing the needs of cancer patients that have no targeted therapies so are are focusing on developing novel therapeutics for the following.
· TNBC - Triple negative breast cancer
· Tyrosine Kinase Inhibitor (TKI) resistant - Non-
small Cell Lung cancer (NSCLC)
· Lung and breast cancer metastasis

They have been investigating a novel biomarker in cancer. A protein called Ran-GTPase RAN (ras-related nuclear protein) , Ran plays an important role in cancer development and progression and is overexpressed in various cancers with prognostic significance and its overexpression is correlated with increased aggressiveness of the cancer cells and with patient deaths.

Ran is a promising cancer therapeutic target; . Ran silencing results in a selective killing effect on cancer cells with stronger activation of cell signalling pathways such as PI3K/Akt/mTORC1 and MEK/ERK; in contrast, loss of Ran in normal cells carries minimal effects. Ran overexpression may play a role in the metastatic development of breast and lung cancers.

Researchers in the university have identified a correlation between survival rates of cancer patients with triple negative breast cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC) with the levels of Ran found in patient cancer cells. In addition, researchers found that suppressing this protein also causes cancer cells already resistant to the first-line and the latest targeted therapeutic treatments, gefitinib and osimertinib, to become re-sensitised to the drug.
Researchers have also used multiple approaches to therapeutic development including conventional screening to identify a class of novel small molecule compounds (NCEs) as Ran inhibitors and produced novel Monoclonal Antibodies formulated in nano-particals (nano-drug) as Ran Inhibitors.

The university is looking for financial co-operations, research co-operations and licencing agreements with the intention of setting up a spin out company, to initially progress with the four stages of the development of the project.
Advantages and Innovations:
Ran inhibitors represent a new class of cancer therapeutics that can be used alone or in combination with current anti cancer drugs as targeted treatments for cancer patients with unmet needs . For example triple negative breast cancer (TNBC) non small cell lung cancer (NSCLC) with acquired resistance to tyrosine kinase inhibitors (TKI´s), breast cancer and lung cancer metastasis are particular areas of promise.
Stage of Development:
Concept stage
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Ran Inhibitor - Patent application filed
two re purposed drugs as Ran Inhibitors in a novel formulation - patent application filed

Partner sought

Type and Role of Partner Sought:
The University are seeking financial agreements licencing agreements and research co operations with the intention of setting up a spin out company to progress the four stages of the development of the project. These co-operations could be from industry and/or academic partners who have the skills in this field of drug development resulting in long term positive results.

Stage 1: Novel Peptide (NPP-1) development to Phase 1
Stage 2: Development of the re purposed drugs in combination with known cancer therapeutics to progress to clinical trials stage
Stage 3: New chemical entity (NCE) development to phase 1 , A Medical Research Council biomedical catalyst funding grant will be submitted
Stage 4: Monoclonal antibodies as a nano-drug to validate in vivo

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06001012 Investigaciones médicas
06001009 Terapia genética - ADN